Ai-Jo focuses her practice on cross-border corporate finance transactions ranging from venture capital/private equity, mergers and acquisitions, joint ventures, co-investments and restructuring in all sectors for a wide range of investors, private and public held companies and financial institutions in Asia, Europe and the United States. Her practice includes:

  • Counseling emerging growth and venture-backed companies throughout each phase of their lifecycle.
  • Advising global private equity/venture capital funds and asset managers in their direct or secondary investments as well as acting for venture and growth equity investors on financing rounds and mergers and acquisition transactions.
  • Negotiating and closing multi-national private equity and acquisition transactions involving targets and clients primarily in the US, China, Hong Kong and South East Asia.


Ai-Jo is an Associate in the Corporate Practice. Ai-Jo has been advising technology and high-growth companies throughout their life cycles on and providing strategic and practical advice in connection with formation and incorporation, restructuring, equity and debt financing transactions, early and late stage venture financings and exit opportunities such as mergers and acquisitions, and other day-to-day legal matter. She also regularly represents investors or corporates primarily located in Asia, Europe and the United States in equity and debt financings, mergers and acquisitions, co-investments and restructuring transactions, and she also works with global and regional private equity funds, venture capital funds, asset management firms and family offices and their portfolio companies on multi-jurisdictional transactions.

Educated in Taiwan, Japan and the United States and with transactional experience globally, Ai-Jo is native in Mandarin, fluent in English and conversational in Japanese. Prior to joining Caldwell, she was an associate in Proskauer Rose’s Hong Kong office.​

Ai-Jo’s experience includes advising:

  • An Indonesian B2B e-commerce company on its US$241 million equity issuance to a leading Indonesian logistics group;​
  • A China-based leading online payment service provider in its US$120 million investment in a China-based facial recognition system developer;​
  • A Hong Kong-based private equity fund manager on the restructuring of a real estate-focused SPC with assets under management over US$100 million;​
  • A global asset and wealth manager on various preferred equity direct investments and co-investments, totaling over US$100 million, in the United States, China and India;​
  • A private equity fund associated with a Singapore-headquartered bank in its US$62 million investment in a China-based self-driving solutions provider;​
  • A China-based leading e-commerce group company in its US$60 million investment in a China-based O2O food delivery services platform;​
  • A Singapore-based property technology company in multiple rounds of equity fundraisings, totaling over US$50 million;​
  • A leading cryptocurrency exchange on its routine venture investments into other digital asset exchanges, wallets and service providers in the United States, Greater China, Southeast Asia and the Middle East, totaling over US$50 million;​
  • A Hong Kong-based family office formed on the formation of a US$30 million joint venture with a US-based tech company to develop a luxury apparel rental subscription service in China;​
  • A leading international mobility and relocation service provider in the US$24 million sale of its China records and information management operations to a global leader in storage and information management services;​
  • A US-based entertainment business company in the US$23 million sale of its China, Hong Kong and US entities to a US-listed company;​
  • An Indonesian online catering startup in multiple rounds of preferred equity financings, totaling over US$20 million; ​
  • An Indonesian-based mobile app technology startup company on its US$20 million preferred equity financings and its convertible note issuances; and​
  • A China state-owned pharmaceutical group company in its US$19 million acquisition of 51% shares of a US-based medical equipment company.​